癌症的精准治疗

IF 1 Q4 PHARMACOLOGY & PHARMACY

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-04-22 DOI:10.1080/23808993.2020.1760089

E. Cartwright, A. Athauda, I. Chau

{"title":"癌症的精准治疗","authors":"E. Cartwright, A. Athauda, I. Chau","doi":"10.1080/23808993.2020.1760089","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Gastric cancer (GC) is a leading cause of cancer-related death and a significant global health burden. Chemotherapy remains the mainstay of treatment in advanced disease and only trastuzumab in combination with upfront fluoropyrimidine/platinum chemotherapy for human epidermal growth factor receptor 2 (HER2) positive disease and ramucirumab together with paclitaxel in the second line have demonstrated a significant survival benefit over chemotherapy alone. Despite the focus on a molecularly targeted approach, treatment gains have been modest and GC remains an area of great unmet need. Areas covered In this review, we provide an overview of the continuum of care in GC, the molecular characterization of GC, targeted therapies currently under investigation and the role of immunotherapy. Expert commentary Gastric cancer is a heterogeneous disease. A targeted approach based upon molecular phenotype holds promise for improving outcomes.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"299 - 311"},"PeriodicalIF":1.0000,"publicationDate":"2020-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1760089","citationCount":"1","resultStr":"{\"title\":\"Emerging precision therapies for gastric cancer\",\"authors\":\"E. Cartwright, A. Athauda, I. Chau\",\"doi\":\"10.1080/23808993.2020.1760089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Introduction Gastric cancer (GC) is a leading cause of cancer-related death and a significant global health burden. Chemotherapy remains the mainstay of treatment in advanced disease and only trastuzumab in combination with upfront fluoropyrimidine/platinum chemotherapy for human epidermal growth factor receptor 2 (HER2) positive disease and ramucirumab together with paclitaxel in the second line have demonstrated a significant survival benefit over chemotherapy alone. Despite the focus on a molecularly targeted approach, treatment gains have been modest and GC remains an area of great unmet need. Areas covered In this review, we provide an overview of the continuum of care in GC, the molecular characterization of GC, targeted therapies currently under investigation and the role of immunotherapy. Expert commentary Gastric cancer is a heterogeneous disease. A targeted approach based upon molecular phenotype holds promise for improving outcomes.\",\"PeriodicalId\":12124,\"journal\":{\"name\":\"Expert Review of Precision Medicine and Drug Development\",\"volume\":\"5 1\",\"pages\":\"299 - 311\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2020-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/23808993.2020.1760089\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Precision Medicine and Drug Development\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23808993.2020.1760089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2020.1760089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

摘要

摘要简介癌症（GC）是导致癌症相关死亡的主要原因，也是全球重大的健康负担。化疗仍然是晚期疾病的主要治疗方法，只有曲妥珠单抗联合前期氟嘧啶/铂化疗治疗人表皮生长因子受体2（HER2）阳性疾病，以及第二行的拉莫昔单抗联合紫杉醇显示出比单独化疗显著的生存益处。尽管重点是分子靶向方法，但治疗效果甚微，GC仍然是一个巨大的未满足需求的领域。涵盖的领域在这篇综述中，我们概述了GC的连续护理、GC的分子特征、目前正在研究的靶向治疗以及免疫疗法的作用。专家评论癌症是一种异质性疾病。基于分子表型的靶向方法有望改善结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Emerging precision therapies for gastric cancer

ABSTRACT Introduction Gastric cancer (GC) is a leading cause of cancer-related death and a significant global health burden. Chemotherapy remains the mainstay of treatment in advanced disease and only trastuzumab in combination with upfront fluoropyrimidine/platinum chemotherapy for human epidermal growth factor receptor 2 (HER2) positive disease and ramucirumab together with paclitaxel in the second line have demonstrated a significant survival benefit over chemotherapy alone. Despite the focus on a molecularly targeted approach, treatment gains have been modest and GC remains an area of great unmet need. Areas covered In this review, we provide an overview of the continuum of care in GC, the molecular characterization of GC, targeted therapies currently under investigation and the role of immunotherapy. Expert commentary Gastric cancer is a heterogeneous disease. A targeted approach based upon molecular phenotype holds promise for improving outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Precision Medicine and Drug Development PHARMACOLOGY & PHARMACY-

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.